GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Total Stockholders Equity

RGC (Regencell Bioscience Holdings) Total Stockholders Equity : $6.72 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Regencell Bioscience Holdings Total Stockholders Equity?

Regencell Bioscience Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $6.72 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Regencell Bioscience Holdings's Book Value per Share for the quarter that ended in Dec. 2024 was $0.01. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Regencell Bioscience Holdings's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.00.

Regencell Bioscience Holdings Total Stockholders Equity Historical Data

The historical data trend for Regencell Bioscience Holdings's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Total Stockholders Equity Chart

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Stockholders Equity
Get a 7-Day Free Trial -2.65 -4.00 17.07 12.03 8.22

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.66 12.03 10.20 8.22 6.72

Regencell Bioscience Holdings  (NAS:RGC) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Regencell Bioscience Holdings's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(6.715-0)/494.489
=0.01

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Regencell Bioscience Holdings's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 6.715
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regencell Bioscience Holdings Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Regencell Bioscience Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Total Stockholders Equity
Comparable Companies
ELAN VTRS LNTH ALKS NBIX UTHR PBH PRGO ALVO AMRX ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
N/A
Address
29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Website
https://www.regencellbioscience.com
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.